Nasal delivery

Abstract

A nasal delivery device for and method of delivering a substance, preferably comprising oxytocin, non-peptide agonists thereof and antagonists thereof, preferably as one of a liquid, as a suspension or solution, or a powder, to the nasal airway of a subject, preferably the posterior region of the nasal airway, and preferably the upper posterior region of the nasal airway which includes the olfactory bulb and the trigeminal nerve, and preferably in the treatment of neurological conditions and disorders.

1 - 63 . (canceled) 
     
     
         64 . A method of treating a neurodegenerative disease with a dose of powdered substance comprising:
 causing a nosepiece of a delivery device to be fitted in a nostril of a subject, the delivery device further including a mouthpiece, a medicament supply unit, and a coupling forming a fluid path between the nosepiece and the mouthpiece;   causing the subject to exhale through the mouthpiece and generate an exhalation flow that (a) creates a positive pressure in an oral cavity of the subject sufficient to cause closure of an oropharyngeal velum of the subject, (b) flows through the fluid path between the nosepiece and the mouthpiece, (c) flows through the nosepiece, and (d) creates a bi-directional flow of exhalation breath through a nasal cavity of the subject when the nosepiece is fitted in the nostril;   causing the exhalation flow to entrain the dose of powdered substance and expel the dose of powdered substance through the nosepiece;   causing the dose of powdered substance to be delivered to an upper posterior, olfactory region of a nasal airway of a subject; and   causing a flow of liquid through the nosepiece after expelling the dose of powdered substance through the nosepiece to promote transfer of the dose of substance delivered to the upper posterior, olfactory region of the nasal airway.   
     
     
         65 . The method of  claim 64 , further including causing a thickening agent to be expelled through the nosepiece with the dose of powdered substance. 
     
     
         66 . The method of  claim 65 , wherein the thickening agent thickens after exposure to moisture, providing for increased residency at the upper posterior, olfactory region of the nasal airway of the subject. 
     
     
         67 . The method of  claim 65 , wherein the thickening agent comprises at least one of pectin, agar-agar, lignin, algin, gums, or cellulose. 
     
     
         68 . The method of  claim 64 , further including causing lactose to be expelled through the nosepiece with the dose of powdered substance. 
     
     
         69 . The method of  claim 64 , wherein the dose of powdered substance ranges from about 1 IU to about 100 IU. 
     
     
         70 . The method of  claim 64 , wherein the dose of powdered substance ranges from about 5 IU to about 80 IU. 
     
     
         71 . The method of  claim 64 , wherein the dose of powdered substance ranges from about 5 IU to about 50 IU. 
     
     
         72 . The method of  claim 64 , wherein the dose of powdered substance ranges from about 5 IU to about 20 IU. 
     
     
         73 . The method of  claim 64 , wherein the dose of powdered substance is delivered once daily. 
     
     
         74 . The method of  claim 64 , wherein the dose of powdered substance is delivered twice daily. 
     
     
         75 . The method of  claim 64 , wherein the neurodegenerative disease is Alzheimer's disease. 
     
     
         76 . The method of  claim 64 , wherein the neurodegenerative disease is Huntington's disease. 
     
     
         77 . The method of  claim 64 , wherein the neurodegenerative disease is Parkinson's disease. 
     
     
         78 . The method of  claim 64 , wherein the powdered substance is oxytocin.